NewsRoom Articles - Page 72 of 154 - PsychedelicNewsWire (PNW)

ThursdayJan 13, 2022 1:56 pm

Veterans with PTSD to Receive Service Dogs Under PAWS Act

Service dogs in the United States are usually given to former service members of the military as a form of support after the soldiers have served the country. Individuals who qualify to receive the free service dogs have to meet various qualifications, which include having emotional or physical disabilities. K9s for Warriors, advocates and Canine Companions have been calling for the Veterans Affairs Department to provide support to veterans with PTSD by giving them service dogs. However, until recently, individuals with mental trauma weren’t eligible to receive these support dogs. Canine Companions offers service dogs to children, adults and veterans…

WednesdayJan 12, 2022 12:37 pm

Four Hidden Psychedelic Truths in ‘The Matrix Resurrections’

“The Matrix” was first released in 1999, and since then, three more sequels have been released: “The Matrix Reloaded,” “The Matrix Revolutions” and “The Matrix Resurrections,” each one more thrilling and captivating than the last. One thing that may catch your eye with this latest release is how trippy the film is, from guided spiritual journeys to flashbacks that bend reality. Today, we look at ways in which “The Matrix Resurrections” is more psychedelic than the first film in the sequence. Slowing time In the first movie, Neo got out of trouble by slowing down the time around him. In…

WednesdayJan 12, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes ‘Milestone’ Step with USPTO Notice of Allowance CYB004

Cybin awarded notice for company’s innovative treatment of anxiety disorders Approval demonstrates company’s dedication to discovery and development of psychedelic-based compounds for addressing mental health Anxiety disorders rank among the most common mental illnesses in the country Cybin (NEO: CYBN) (NYSE American: CYBN) has taken another step forward in its strategic plan to strengthen its position as leading innovator in developing putative psychedelic compounds. The company has received a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for its patent application for an innovative treatment of anxiety disorders (https://ibn.fm/8hMWh). Cybin announced that it has been awarded a USPTO…

TuesdayJan 11, 2022 1:03 pm

Psychedelics May Shed Light on How Perception Occurs

Anil Seth, a neuroscientist at the University of Sussex, has been studying how the brain helps individuals perceive the world around them. The researcher is interested in what psychedelics like LSD can reveal to us about how the brain develops different perceptions. Seth has tried LSD and ayahuasca, both experiences leaving him with a strengthened conviction that these substances possess the potential to teach us about the workings of the brain, which produces perceptions. He isn’t the only advocate, as more neuroscientists, armed with computational models of the brain, EEG recordings, fMRI scans and volunteer reports, try to understand how…

MondayJan 10, 2022 1:36 pm

University of Texas-Austin Launches Center for Psychedelic Research and Therapy

The University of Texas at Austin recently established a Center for Psychedelic Research and Therapy. This comes months after the state’s governor signed a proposal that instructs the state to conduct research on the benefits and risks of ketamine, MDMA and psilocybin for veterans. Prof. Charles B. Nemeroff, the center’s co-lead, stated that the center would bring more scientific expertise and rigor to study psychedelic therapy. Nemeroff is also the chair of the Department of Behavioral Sciences and Psychiatry at the Dell Medical School. The center, which is the first of its kind in the state, will allow researchers to…

MondayJan 10, 2022 12:21 pm

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Announces Completion of Target-Based Model in Its AI-Driven Drug Discovery Program

The AI-driven drug discovery program uses not only artificial intelligence but also machine learning, which is a relatively new concept and is continuously expanding The use of artificial intelligence in the drug development space may help eliminate or reduce the manual operations that a company typically must undergo to identify and make necessary improvements to drugs The new model will allow the company to rapidly screen billions of structures promoting near term patent filings for novel psychedelic molecules Mydecine has already been able to eliminate unsuccessful candidates early on with the use of this technology Mydecine’s primary focus is the…

MondayJan 10, 2022 12:04 pm

Congressman Calls for Liberalized Access to Psilocybin; Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Positions for Growth Within Psychedelics Sector

Congressman Earl Blumenauer recently wrote to his peers, urging them to petition the DEA to permit terminally ill patients to use psilocybin as part of their treatment Although 41 states permit terminal patients to try investigational drugs, psilocybin continues to be banned by the DEA Change seems to be coming within the sector as evidenced by its decriminalization in cities such as Denver and Oakland Delic Corp has positioned itself as a leading psychedelic wellness platform, with business interests in ketamine infusion clinics, media, event management, and psilocybin research In mid-December, Representative Earl Blumenauer circulated an open letter to his…

MondayJan 10, 2022 10:26 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO Participation in Upcoming Events Recognizes Company Expertise

CEO to participate in panel discussion, fireside chat focusing on psychedelics The company is engineering next-generation psychedelic molecules as it works to transform the mental health treatment landscape CYBN is implementing a three-pillar strategy Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics, is gaining recognition as a leader in the psychedelic space. Evidence of this can be seen in the Cybin CEO’s upcoming participation in two virtual investor conferences (https://ibn.fm/1zAF4). The company announced that CEO Doug Drysdale has been invited to participate in a panel discussion titled "Psychedelics: More Than Just a Trip" during…

FridayJan 07, 2022 1:38 pm

A Recap of How Psychedelics Fared in 2021

At the start of last year, only a few psychedelic companies were trading on the exchange markets, with Compass Pathways (NASDAQ: CMPS) and Mind Medicine (NASDAQ: MNMD) (NEO: MMED) (“MindMed”) among them. However, this year saw a number of IPOs, which increased the total number of public psychedelic companies trading on the market. These companies include Atai Life Sciences (NASDAQ: ATAI), Field Trip Health (NASDAQ: FTRP) and Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF). This increase brought more resources to the space, which helped ensure its survival. In addition, it widened the scope of treatments being researched as well as the…

FridayJan 07, 2022 9:00 am

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Signs LOI with Maya to Co-Develop a Prescription Digital Therapeutics Platform Targeting a Trifecta Approach to Patient Care

Mydecine has signed a letter of intent with Maya detailing a collaborative partnership to develop a novel digital therapeutics (“DTx”) platform The DTx platform is expected to create a three-pronged approach to patient care by combining Mydecine’s Mindleap digital health platform with its medication-based treatments According to COO Damon Michaels, the new platform will provide improved adherence to treatment protocols, patient experience, biometric insights, and post-approval insurance reimbursements Both companies intend to pursue rigorous studies to achieve FDA clearance Regarded as the convergence of health care and software that has resulted in a new crop of life sciences technology helping…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000